{
    "clinical_study": {
        "@rank": "117749", 
        "acronym": "EHTIC", 
        "arm_group": [
            {
                "arm_group_label": "TT.173", 
                "arm_group_type": "Experimental", 
                "description": "It is applied directly to the bleeding of the donor site"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "It is applied directly to the bleeding of the donor site"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine  the haemostatic efficacy of TT-173, reducing the\n      bleeding time in the donor site of skin grafting."
        }, 
        "brief_title": "Determine the Haemostatic Efficacy of TT-173, Reducing the Bleeding Time in the Donor Site of Skin Grafting", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Burns", 
            "Traumatic Lesions"
        ], 
        "detailed_description": {
            "textblock": "As the TT-113 has been cleared for use as a topical hemostatic agent, the proposed study\n      will further investigate the safety and efficacy of TT-113 in the donor site of sking\n      grafting"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subjects who signed the informed consent.\n\n          -  Subjects that have to undergo a skin graft.\n\n          -  Subjects of both sexes older than 18 years.\n\n          -  Subjects that present a burn or traumatic skin injury affecting less than 30% of\n             corporal surface.\n\n          -  Subjects with a platelet count not compatible with pathology.\n\n          -  Subjects who present haemogram results not indicative of any of the situations\n             mentioned in the exclusion criteria.\n\n          -  Subjects who present biochemical results not indicative of any of the situations\n             mentioned in the exclusion criteria.\n\n          -  Subjects who present coagulation parameters not indicative of any of the situations\n             mentioned in the exclusion criteria.\n\n          -  Women of childbearing age who take contraceptive measures and are willing to maintain\n             them until the end of follow up of this study.\n\n          -  Women of childbearing age who present a negative test pregnancy at the moment of\n             study inclusion\n\n        Exclusion Criteria:\n\n          -  -Subjects with personal or family history of abnormal hemorrhagic episodes.\n\n          -  Subjects affected of any kind of congenital or acquired coagulopathies.\n\n          -  Subjects that present a burn or traumatic skin injury affecting more than 31% of\n             corporal surface.\n\n          -  Subjects affected of any blood, heart or liver disease, chronic renal failure, severe\n             chronic obstructive pulmonary disease, active oncologic process in the past three\n             months, diabetes type I or who has suffered a stroke.\n\n          -  Subjects who experienced excessive bleeding after surgical procedures, childbirth or\n             tooth extraction.\n\n          -  Subjects affected by any acute infectious disease.\n\n          -  Subjects affected of any systemic disease that may worsen the prognosis if any\n             adverse effect occurs (decompensated type 2 diabetes mellitus, uncontrolled\n             hypertension or severe systemic disease).\n\n          -  Subjects who should take antiplatelet therapies one week before and 48 hours after\n             the surgery (AAS, trifusal, dipiridamol, clopidogrel, abciximab).\n\n          -  Subjects with known hypersensitivity or allergy to any component of the drug.\n\n          -  Subjects who consume abuse drugs excluding cannabis and its derivatives.\n\n          -  Subjects who are unable to follow or understand properly the instructions and\n             requirements of the study.\n\n          -  Subjects who are not free to give informed consent or who are mentally incapacitated\n             to the discretion of investigators.\n\n          -  Subjects who participate or have participated in the past three months in another\n             clinical trial with drug treatment.\n\n          -  Subjects that are the investigators, collaborators, nurses, center employees or any\n             other person directly related to the development of the protocol.\n\n          -  Subjects who are positive to HIV or HCV serology, or who present active HBV\n             infection.\n\n          -  Subjects who are pregnant or lactating."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "78", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02012569", 
            "org_study_id": "THO-IM_01-CT", 
            "secondary_id": "2013-002784-25"
        }, 
        "intervention": [
            {
                "arm_group_label": "TT.173", 
                "description": "Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times  for about 1 minute apart each  application after skin graft obtention.", 
                "intervention_name": "TT-173", 
                "intervention_type": "Drug", 
                "other_name": "topical hemostatic agent"
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hemostatics"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "skin grafting", 
            "elective treatment"
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": {
            "contact": {
                "email": "ramonlopez@thrombotargets.com", 
                "last_name": "Ram\u00f3n L\u00f3pez", 
                "phone": "+34936642040"
            }, 
            "facility": {
                "address": {
                    "city": "Castelldefels", 
                    "country": "Spain", 
                    "state": "Barcelona", 
                    "zip": "08860"
                }, 
                "name": "Thrombotargets Europe"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Randomized, Controlled, Single Blind Study to Evaluate the Haemostatic Efficacy and Safety of TT-173 Applied in the Donor Site of Patients Undergoing Skin Graft", 
        "overall_contact": {
            "email": "ramonlopez@thrombotargets.com", 
            "last_name": "Ram\u00f3n L\u00f3pez", 
            "phone": "+34 936642040"
        }, 
        "overall_official": {
            "affiliation": "Thrombotargets Europe", 
            "last_name": "Ramon lopez, Manager", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Reducing the bleeding time in the donor site of skin grafting", 
            "safety_issue": "No", 
            "time_frame": "10 min"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02012569"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Number of Adverse Events", 
                "measure": "Safety and tolertability", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Cmax, Tmax, AUC and bioavailability", 
                "measure": "Systemic absorption of the product", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "description": "Antibody concentration", 
                "measure": "Immunogenicity", 
                "safety_issue": "Yes", 
                "time_frame": "1 month"
            }
        ], 
        "source": "Thrombotargets Europe S.L", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Thrombotargets Europe S.L", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}